← Back to all announcements

Dr. Steven Archer secures nearly $4-million for research in cardiology

  • Published Mon Jun 1st 2015

    Over $16 million in funding from the Canada Foundation for Innovation’s (CFI) 2015 Innovation Fund will support research projects in dark matter, cardiology, chemistry and nanotechnologies at Queen's University.

    “Thanks to the grants from the CFI’s Innovation Fund, four researchers from Queen’s and their teams will be able to take their research activities to the next level and advance their leading-edge research,” says Vice-Principal (Research) Steven Liss. “Our success with this funding highlights Queen’s as one of the most research-intensive institutions in Canada.”

    Stephen Archer (Cardiology, $3,830,497) – This CFI funding was awarded to Dr. Archer, Tier 1 Canada Research Chair in Mitochondrial Dynamics and Translational Medicine and Head of the Department of Medicine, and his team in the Queen’s Cardiopulmonary Unit (Q-CPU). This international team will work to ensure a better quality of life for patients with pulmonary arterial hypertension (PAH) – the obstruction of lung arteries, which can lead to fatal right heart failure. Q-CPU investigators are striving to discover and test new treatments for this heart and lung disease. They have a track record of moving discoveries from Bench to Bedside, including performing some of the early work demonstrating the safety and utility of sildenafil (Viagra®) in the treatment of PAH and the use of dichloroacetate to treat PAH and cancer. The team at Queen’s includes, the CCR Group, led by Dr. Don Maurice, and a talented group of respirologists, epidemiologists, cardiologists, hematologists and neurologists. With its corporate and knowledge translation partners, Q-CPU will support comprehensive understanding of PAH from molecules to populations, identify new therapeutic targets and test new therapies for PAH and right heart failure. Q-CPU is supported by a network of PAH centers in three countries, with sites in Edmonton, Salt Lake City, Sao Paulo, Minneapolis, Ottawa and Kingston. The proposed research will enhance the health of Canadians by creating innovative new clinical therapies for PAH through the development and evaluation of experimental therapeutics, the study of pharmaco-epidemiology, health services utilization and epidemiology of PAH. Q-CPU will be housed in a state of the art 8,000-square-foot facility within the Biosciences Complex.

    Find the full story here.